Policy & Regulation
CHMP issues positive opinion for DAWNZERA in hereditary angioedema
14 November 2025 - Ionis Pharmaceuticals Inc (Nasdaq:IONS), a US-based provider of RNA-targeted medicines, and Japanese healthcare company Otsuka Pharmaceutical Co Ltd announced on Friday that the Com...
Merck to acquire Cidara Therapeutics in USD9.2bn deal to expand antiviral portfolio
14 November 2025 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, on Friday announced a definitive agreement to acquire Cidara Therapeutics Inc (Nasda...
Eisai and BioArctic's Leqembi gains UK regulatory approval for IV maintenance treatment of Alzheimer's disease
14 November 2025 - Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) and its Japanese partner Eisai Co Ltd (TYO:4523) announced on Thursday that the UK's Medicines and Healthcare...
IVI RMA Global Expands Footprint with Acquisition of ART Fertility Clinics, Establishing Middle East as Fifth Operating Region
14 November 2025 - IVI RMA Global, recognised as the world's leading reproductive medicine platform, has confirmed that following the completion of its acquisition of ART Fertility Clinics ("...
EirGenix signs second global exclusive licensing deal with Sandoz
13 November 2025 - Taiwan-based contract development and manufacturing organisation EirGenix Inc (TWSE:6589) announced on Wednesday that it has signed a second global exclusive licensing agreement wit...
Longeveron secures US patent for stem cell therapy targeting aging-related frailty
12 November 2025 - American clinical-stage biotechnology company Longeveron Inc. (NASDAQ: LGVN) announced on Wednesday that it has received a new United States patent for its proprietary mesenchymal s...